GlassScriptPhysician profile
Dennis S Devinney
NPI 1457398935
$267,120.27
in general payments reported to CMS, 2019-2025
20 companies · $41K in 2025
The $41K reported for 2025 was more than what 94% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $30K · 2021: $42K · 2022: $34K · 2023: $43K · 2024: $44K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $118K · Travel and Lodging: $6,446 · Food and Beverage: $2,996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $118,428.24 |
| Travel and Lodging | $6,445.53 |
| Food and Beverage | $2,995.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $145,261.32 | 2020-2025 | Knee & Hip Instruments |
| Stryker Corporation | $54,259.86 | 2019-2025 | Aequalis Perform, Blueprint Patient Specific Instrumentation, Mako |
| Wright Medical Technology, INC. | $31,401.26 | 2019-2020 | |
| Advanced Orthopaedic Solutions, INC. | $26,273.89 | 2019-2020 | |
| Encore Medical, LP | $6,300.00 | 2019-2021 | |
| Pylant Medical | $2,676.68 | 2019-2025 | |
| Bioventus LLC | $365.55 | 2019-2025 | Durolane, Durolane, Exogen Ultrasound Bone Healing System |
| Ferring Pharmaceuticals INC. | $158.23 | 2019-2025 | Euflexxa |
| Ablative Solutions, INC. | $76.74 | 2022 | |
| Medtronic, INC. | $60.09 | 2023 | Osteocool Rf Ablation System |
| Abbott Laboratories | $57.54 | 2019-2025 | Proclaim |
| Orthofix Medical, INC. | $42.03 | 2025 | Physio-Stim |
| Vertex Pharmaceuticals Incorporated | $41.01 | 2024-2025 | |
| Depuy Synthes Sales INC. | $33.70 | 2023-2025 | Monovisc, Orthovisc, Tfn-Advance |
| Pacira Pharmaceuticals Incorporated | $32.52 | 2022-2023 | Zilretta, Iovera, Exparel |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innovation Technologies INC | $19.66 | 2022 | |
| Polynovo North America LLC | $17.65 | 2025 | Novosorb Btm |
| Integra Lifesciences Corporation | $15.62 | 2021 | |
| Sanara Medtech INC. | $13.96 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.96 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Devinney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.